The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study.

ABSTRACT:

Background

We aimed to evaluate the efficacy of fulvestrant and its affecting clinical factors, including the optimal sequencing of fulvestrant and chemotherapy in a real-life cohort.

Methods

The data of 256 metastatic hormone-positive breast cancer patients treated with fulvestrant were evaluated. The association of clinical factors with survival was analyzed with Kaplan-Meier and Cox-regression analyses.

Results

The median age of patients was 57 years. More than half of the patients used fulvestrant in later lines and after chemotherapy (75.8%). The median progression-free (PFS) and overall survival (OS) of all cohort were 6.05 ± 0.56 and 29.70 ± 1.61 months, respectively. Primary endocrine resistance (HR: 1.989, 95% CI: 1.430-2.766, <0.001), use of fulvestrant afte

SUBMITTER: Guven DC 

PROVIDER: S-EPMC10395701 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature